阿帕替尼治疗晚期非小细胞肺癌的疗效分析
对照和多中心临床研究显示出生存获益,2014年10月甲磺酸阿帕替尼被CFDA批准用于晚期胃腺癌 胃食管结合部腺癌三线或三线以上治疗,但目前在尚未批准用于其他实体恶性肿瘤,目前正在进行肺癌、肝癌、食管癌、结直肠癌等多种恶性肿瘤的Ⅱ/Ⅲ期临床试验,以探讨其单独或联合抗肿瘤活胜。在剂量选择方面,2012年中国临床肿瘤学会(ChineseSceiety ofClinicalOncology,CSCO)年会报道,在体外及动物实验中,阿帕替尼治疗组的课鼠牛存期较对照组明显延长,生存期与阿帕替尼的剂量强度呈正相关。
参考文獻:
[1]Ding J, Chen X, Dai X, et al. Simultaneous determination ofapatinib and its four major metabolites in human plasma using liquidchromatography-tandem mass spectrometry and its application to aphannacokinetic study[J]. J Chromatogr B Analyt Technol BiomedLife Sci,2012,895-896:108-115
[2]Zhang H. Apatinib for molecular targeted therapy in tumor[J].Drug Des Devel Ther, 2015, 9: 6075-6081.
[3]秦叔逵,李进.阿帕替尼治疗胃癌的临床应用专家共识[J].临床肿瘤学杂志,2015,20(9): 841-847.
[4]QIN Shukui, LI Jin. Experts consensus on the clinicalapplication of apatinib in gastric cancer treatment[J].Chinese ClinicalOncology,2015, 20(9):841-847.
[5]Zhu ,et a1.Apatinib,a new small molecular VEGFR2 inhibitor,suppresses the activity of lung cancer stem cells[J],J Clin Invest.2010,120(1):41-50.
[6]Jayson GC, Kerbel R, Ellis LM, et al. Antiangiogenic therapyin oncology: current status and future directions[J].Lancet,2016,388(10043):518-529.